Drug distributor Cardinal Health on Thursday raised its fiscal 2025 adjusted profit forecast as strong demand for costly specialty medicines and branded drugs drove sales at its pharmaceuticals unit.

Cardinal (CAH) delivered earnings and revenue surprises of 10.29% and 0.69%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

In a report released yesterday, Stephen Baxter from Wells Fargo maintained a Hold rating on Cardinal Health (CAH – Research Report), with a ...

Morgan Stanley analyst Erin Wright maintained a Buy rating on Cardinal Health (CAH – Research Report) today and set a price target of $136.00.

Cardinal Health, Inc. CAH is scheduled to report fiscal second-quarter 2025 results on Jan. 30, before the opening bell. In ...

Cardinal Health (NYSE:CAH – Free Report) had its price objective hoisted by JPMorgan Chase & Co. from $132.00 to $142.00 in a ...

We recently published a list of Jim Cramer’s Latest Calls: 10 Stocks to Buy or Sell. In this article, we are going to take a ...

Cardinal Health, Inc. operates as a healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. It provides customized solutions for hospitals ...

Cardinal Health gets downgraded to a hold, from my buy rating last February, agreeing with the Seeking Alpha quant system rating. While macro-level demand for medical supplies is expected to keep ...

Cardinal Health Inc (NYSE:CAH). shares have reached an unprecedented peak, with the stock hitting an all-time high of $130.1.

Cardinal Health announced construction is underway on a new distribution center in Fort Worth, Texas, which will support its at-Home Solutions business, a medical supplies provider that serves more ...

Merit Financial Group LLC purchased a new position in Cardinal Health, Inc. (NYSE:CAH – Free Report) during the fourth quarter, Holdings Channel reports. The firm purchased 3,660 shares of the company ...